Neuronetics Stock Price, News & Analysis

Neuronetics (NASDAQ: STIM) reported preliminary revenues for Q3 2021, expecting approximately $13.8 million, lower than previously estimated guidance of $15.0 million to $16.0 million. Full-year revenue is forecasted to be between $53.3 million and $54.3 million. CEO Keith J. Sullivan attributed the shortfall to the new sales team's productivity challenges amid extended sales cycles influenced by the Covid-19 pandemic. Despite this, the company made progress on strategic initiatives, including successful marketing campaigns and productive discussions with the FDA regarding potential label expansions.

Neuronetics, Inc. (NASDAQ: STIM) has entered an exclusive five-year commercial agreement with Success TMS, which will utilize Neuronetics’ NeuroStar Advanced Therapy exclusively to treat patients with treatment-resistant major depressive disorder (MDD). Additionally, Neuronetics has made a strategic investment of $10 million to support Success TMS's growth. Success TMS aims to triple its size in the next two years, having provided over 250,000 treatments across 30 sites in six states. This partnership emphasizes the commitment to improving patient access to non-drug therapies for neurohealth disorders.

Neuronetics, a medical technology company focused on neurohealth, has announced new partnerships with mental health advocates for National Depression Education and Awareness Month. The company’s NeuroStar^® Therapy leads the non-invasive treatment for depression. The campaign, featuring Dr. Melissa Shepard, aims to educate patients and physicians on this breakthrough technology. Additionally, NeuroStar is sponsoring key events to raise awareness and promote mental health research. With over four million treatments delivered, NeuroStar remains committed to transforming lives through effective non-drug therapies.

Neuronetics (NASDAQ: STIM) has partnered with Zion Healing to become the exclusive supplier of TMS equipment for Zion's mental health clinics. This agreement aims to enhance patient access to NeuroStar® Advanced Therapy, a non-invasive treatment for depression. Robert Beatty, CEO of Zion Healing, emphasized the urgent need for mental health services, while Neuronetics' President, Keith J. Sullivan, highlighted the partnership's potential to expand treatment availability. NeuroStar has delivered over 4 million treatments, demonstrating its efficacy in adult patients with major depressive disorder.

Neuronetics, Inc. (NASDAQ: STIM) announced the launch of an enhanced website aimed at improving the user experience for patients seeking information on advanced depression treatments. Market research reveals that 67% of Major Depressive Disorder patients are dissatisfied with current treatments. The new site provides essential resources, including a physician locator tool and success stories, to empower patients and healthcare providers. With rising depression rates post-COVID-19, this initiative underscores Neuronetics' commitment to addressing unmet mental health needs.

Neuronetics (NASDAQ: STIM) has appointed Megan Rosengarten to its Board of Directors, expanding the board to eight members. Rosengarten brings over two decades of experience in medical technology, currently serving as President of Surgical Robotics at Medtronic. She previously held roles at Hologic, Covidien, and Johnson & Johnson. Her expertise in product development and marketing is expected to enhance Neuronetics' growth strategy for its NeuroStar Advanced Therapy for Mental Health, which is FDA-cleared for treating major depressive disorder. The company aims to increase awareness and adoption of this innovative therapy.

Neuronetics, a medical technology company, reported a 46% revenue increase to $14.2 million for Q2 2021, driven by a 65% rise in U.S. treatment session revenue. The company highlighted 83% response and 62% remission rates from its NeuroStar Outcomes Registry. While gross margin improved to 80.6%, operating expenses rose to $18 million. A net loss of $(7.5) million was reported, slightly better than the previous year's $(7.8) million. For full-year 2021, revenue is projected between $59 million and $63 million, with Q3 expectations between $15 million and $16 million.

Neuronetics, a commercial-stage medical technology company focused on improving the quality of life for psychiatric disorder patients, announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021. CEO Keith Sullivan and CFO Steve Furlong will present at 9:30 am ET. The presentation will be available via live audio webcast on the company’s investor relations page, with a replay accessible for 90 days. Neuronetics’ flagship product, NeuroStar, is a FDA-cleared therapy for major depressive disorder.

Neuronetics, based in Malvern, PA, announced it will release its second quarter financial and operational results on August 3, 2021, before the market opens. A conference call will follow at 8:30 a.m. ET to discuss the results. Investors can listen via a webcast on Neuronetics' investor relations site or by dialing in using a provided telephone number and confirmation code. The company specializes in medical technology aimed at improving the quality of life for patients with psychiatric disorders, notably through its FDA-cleared NeuroStar® Advanced Therapy System.